 The notion behind Allogene was to create a 'next generation CAR-T' which was not tailored to a single individual, as YESCARTA was, but rather could be used in multiple patients, an allogeneic CAR-T. Pfizer received a 25% stake in Allogene and two seats on the company's board, while Allogene received rights to sixteen pre-clinical CAR-T assets and one Phase 1 allogeneic CAR-T clinical asset.Allogene's Series A funding was US$300 million, including Texas Pacific Group, University of California, Two River—and even Gilead as participants, among others.In October 2019, Allogene's initial public offering netted US$324 million and a capital valuation of US$3 billion.